- Neuropathic pain is the most common individual chronic pain type among breast cancer survivors.
- Central sensitization pain is more common among recipients of hormone therapy.
Why this matters
- Breast cancer (BCa) survivors with chronic pain should be referred to pain specialists.
- Hormone therapy recipients should be advised of the risk of central sensitization pain.
- Cross-sectional cohort (n=91) of BCa patients with chronic pain.
- Pain type was studied by Visual Analog Scale for pain (VAS), Douleur Neuropathique 4 Questionnaire (DN4), Margolis Pain Diagram, Central Sensitization Inventory (CSI).
- Pain effect on health-related QoL (HRQoL) was studied by Short form 36 (SF-36).
- Funding: No external sources.
- Neuropathic pain and mixed pain were the most common pain types:
- neuropathic pain, 25.3%;
- nociceptive pain, 18.7%;
- central sensitization, 15.4%; and
- mixed pain (any combination of neuropathic, nociceptive, and/or central sensitization), 40.6%.
- The pain groups were significantly different in HRQoL "general health" subscale by one-way analysis of variance (P=.04).
- Central sensitization was nearly 26 times more common among hormone therapy recipients than nonrecipients (OR, 25.95; P=.03).
- Cross-sectional, observational design.
- Small number of subjects.